Journals / Turkish Journal of Pharmaceutical Sciences / 2018 / Cilt: 15 - Sayı: 2

Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish Patients with Major Depressive Disorder

Majör Depresif Bozukluğu Olan Türk Hastalarında CYP3A4 -392A>G Genotip ve Allel Frekansı

Pages
200–206
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, the results of the study were compared with those of other ethnic groups and they displayed pronounced differencesamong other ethnic groups, especially black subjects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Genetic polymorphisms may help for individualized drug dosing and improved therapeutics.
📊
Key Findings & Data:CYP3A4 is responsible for the metabolismof more than 50% of the commonly used drugs and metabolizes typical antipsychotic medications and antidepressant drugs.
💡
Conclusion & Impact:Furthermore, the results of the study were compared with those of other ethnic groups and they displayed pronounced differencesamong other ethnic groups, especially black subjects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Genetic polymorphisms may help for individualized drug dosing and improved therapeutics. CYP3A4 is responsible for the metabolismof more than 50% of the commonly used drugs and metabolizes typical antipsychotic medications and antidepressant drugs. The objective of thestudy was to assess the genotype and allele frequencies of CYP3A4 -392A>G in Turkish patients with major depressive disorder receiving anySSRIs and to compare these results with the frequencies of other ethnic groups.Materials and Methods: Genotyping analyses of CYP3A4 -392A>G was conducted on 84 Turkish patients using the PCR-RFLP technique.Results: The allele frequencies were found as 0.982 (A) and 0.018 (G) for CYP3A4 -392A>G. The genotype frequencies were determined as 0.976(AA), 0.012 (AG), and 0.012 (GG). The genotype frequencies were consistent with the Hardy-Weinberg equilibrium.Conclusion: The genotype and allele frequencies of CYP3A4 -392A>G were determined to be low in Turkish patients with major depressive disorderreceiving SSRIs. Furthermore, the results of the study were compared with those of other ethnic groups and they displayed pronounced differencesamong other ethnic groups, especially black subjects.

Özet

Amaç: Genetik polimorfizmler, bireyselleştirilmiş ilaç dozlaması ve geliştirilmiş terapötikler için yardımcı olabilir. CYP3A4 yaygın olarak kullanılan ilaçların %50’sinden fazlasının metabolizmasından sorumludur ve tipik olarak antipsikotik ilaçlar, antidepresan ilaçları metabolize eder. Bu çalışmanın amacı, herhangi bir SSGİ alan majör depresif bozukluğu olan Türk hastalarında CYP3A4 -392A>G’nin genotip ve alel frekanslarını değerlendirmek ve sonuçlarımızı diğer etnik gruplardaki frekanslarla karşılaştırmaktır. Gereç ve Yöntemler: CYP3A4 -392A>G’nin genotiplendirme analizi, 84 Türk hastasında PZR-RFLP tekniği ile gerçekleştirilmiştir. Bulgular: CYP3A4 -392A>G için allel frekanslarının 0.982 (A) ve 0.018 (G) olduğu saptanmıştır. Genotip frekanslarının ise 0.976 (AA), 0.012 (AG) ve 0.012 (GG) olduğu tespit edilmiştir. Genotip frekansları Hardy-Weinberg dengesiyle uyumludur. Sonuç: CYP3A4 -392A>G’nin düşük frekansı, CYP3A4 ilaç metabolize edici enzimin SSGİ’ler üzerinde oldukça düşük bir etkisinin olacağı önerilmektedir. Bunun yanı sıra, araştırmanın sonuçları diğer etnik gruplarla karşılaştırılmış olup etnik grup farklılıklarının özellikle de siyah deneklerde belirlenmiştir.

🔖

Cite This Article

UÇKUN, Z., ÖZDEMİR, H., BASKAK, B., ÖZGÜVEN, H. D., KIZIL, E. T. Ö., SÜZEN, H. S. (2022). Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish Patients with Major Depressive Disorder. Turkish Journal of Pharmaceutical Sciences, Cilt: 15 - Sayı: 2, 200–206. https://ajindex.com/articles/613856

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ota T, Kamada Y, Hayashida M, Iwao-Koizumi K, Murata S, Kinoshita K. Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population. Int J Med Sci. 2015;12:78-82
  2. Ruzilawati AB, Suhaimi AW, Gan SH. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta. 2007;383:158-162
  3. Nogal A, Coelho A, Catarino R, Morais A, Lobo F, Medeiros R. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population. Cancer Genet Cytogenet. 2007;177:149-152
  4. Maruf AA, Ahmed MU, Azad MA, Ahmed M, Hasnat A. CYP3A genotypes in Bangladeshi tuberculosis patients. Bangladesh Med Res Counc Bull. 2012;38:1-5
  5. Salameh G, Al Hadidi K, El Khateeb M. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population. Environ Toxicol Pharmacol. 2012;34:23-33
  6. Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, Wang DM, Hu S. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56:415-422
  7. Keshava C, Mccanlıes EC, Weston A. CYP3A4 PolymorphismsPotential Risk Factors for Breast and Prostate Cancer: A HuGE Review. Am J Epidemiol. 2004;160:825-841
  8. Kumar V, Singh S, Yadav CS, Ahmed RS, Gupta S, Pasha ST, Tripathi AK, Banerjee BD. CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol. 2010;29:126-130
  9. Ayano G. Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 3A4 Enzyme and Relevant Drug Interactions: Review of Articles. Austin J Psychiatry Behav Sci. 2016;3:1-3
  10. Uckun Z, Baskak B, Ozdemir H, Ozel-Kizil ET, Devrimci Ozguven H, Suzen HS. Association Between the 5-HTTLPR Polymorphism and Response to Citalopram in Turkish Patients with Major Depressive Disorder. Turk J Pharm Sci. 2016;13:145-158
  11. Cavalli SA, Hirata MH, Hirata RD. Detection of MboII polymorphism at the 5’ promoter region of CYP3A4. Clin Chem. 2001;47:348-351
  12. Uckun Z, Baskak B, Ozel-Kizil ET, Ozdemir H, Devrimci Ozguven H, Suzen HS. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015;40:672-679
  13. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ. Application of Pharmacogenomics in Clinical Pharmacology. Toxicol Mech Methods. 2006;16:89-99
  14. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4